Uniqure withdraws €1m drug Glybera from...With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now, Uniqure has decided to terminate post-marketing studies required for prolongation of its … more ➔
GE partner Synpromics completes financing...Synthetic promoter and gene expression specialist Synpromics has completed a £5.2m (€6.2m) financing round with existing investors. more ➔
Galapagos raises US$338mAutoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS. more ➔
Allergan and Novartis combine NASH candida...Irish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH candidates cenicriviroc (Allergan) and FXR agonist LJN452 (Novartis). more ➔
bestbion dx to market sphingotecs predic...sphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotecs innovative sepsis and congestive heart failure test (sphingotest bio-ADM) and acute kidney function monitoring … more ➔
Galenica exercises over-allotment optionFollowing its CHF1.901bn IPO at SIX Swiss Exchange on 7 April, Galenica Santé has announced full excercise of the over-allotment option worth CHF248m. more ➔
Spain establishes world-class disease mode...Spanish Economy Minister Luis de Guindos and EMBL Director-General Iain Mattaj have inked an agreement to host a world-class tissue imaging facility in Barcelona. The EMBLs 6th site in Europe will … more ➔
Roches alectinib superior to crizotinibAfter having received market authorisation in Europe and the US for alectinib as second-line treatment for ALK-positive NSCLC, Roche presents data that qualifies the oral drug as first-line therapy. more ➔
Nanobiotix completes €25m private placem...French cancer specialist Nanobiotix has closed a €25.1m placement of shares being issued to qualified and institutional investors in the US and Europe. The company will use to funds go push commercialisation … more ➔
Adaptimmune raises US$42mAs cancer immune therapy specialist Adaptimmunes R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds. more ➔